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Summary 19 
The genus Candida contains a number of yeast species which are 20 
opportunistic pathogens and are associated with life-threatening infections in 21 
immunocompromised individuals.  Provision of appropriate therapy relies on the rapid 22 
identification of the infecting species and existing methods of identifying Candida 23 
species in clinical samples are time and resource intensive and are not always 24 
specific enough to differentiate between drug-susceptible and drug-resistant species. 25 
We have previously developed a system for the rapid detection of yeast pathogens in 26 
clinical samples using PCR followed by hybridisation with a suite of five species-27 
specific, electrochemically labelled DNA probes.  The limit of detection of the assay 28 
was shown to be 37fg (≈ one genome) per reaction using extracted genomic DNA. 29 
We carried out a study to test the limit of detection of one of the probes, CA PR3, 30 
using blood samples from a healthy donor that were spiked with genomic DNA or 31 
with C. albicans cells.  Our results demonstrate a limit of detection of 37fg ml-1 (≈ 1 32 
genome ml-1) of blood using extracted DNA or 10c.f.u ml-1 of blood using C. albicans 33 
cells indicating that the assay is capable of detecting C. albicans nucleic acid at 34 
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Introduction 39 
 Some species of fungi are capable of causing life-threatening invasive 40 
infections most commonly in individuals with a weakened immune system due to 41 
underlying disease or immuno-suppressive therapy (Pfaller & Diekema, 2010) and 42 
species of the genus Candida are by far the most prevalent, being responsible for 70-43 
80% of diagnosed fungal bloodstream infections in the United States (Fridkin and 44 
Jarvis, 1996; Trick et al., 2002).  C. albicans is usually the most commonly isolated 45 
species from patients with invasive candidiasis, accounting for approximately 45-65% 46 
of cases. 47 
 48 
Diagnosis of invasive candidiasis can be difficult and culture remains the ‘gold 49 
standard’ for definitive diagnosis of invasive fungal infections.  However, identification 50 
of fungi by culture and subsequent biochemical tests is time consuming (Morris et al., 51 
1996) and has been reported to lack sensitivity (Pemán & Zaragoza, 2009).  A 52 
number of nuceic acid-based assays for detecting fungi have been developed (e.g. 53 
Hata et al., 2008; Borman et al, 2008; Lau et al., 2008) which are capable of species-54 
level identification and some have been shown to be capable of direct detection of 55 
fungal DNA from blood (e.g. McMullan et al., 2008; Zhao et al., 2009).   56 
 57 
A novel method for detection of nucleic acid was developed by Hillier et al. (2004a; 58 
2004b) using oligonucleotide probes labelled with the electroactive compound 59 
ferrocene and detection was performed using differential pulse voltammetry (DPV) on 60 
solid electrodes.  We previously extended this work and developed a pan-fungal 61 
probe as well as a suite of species-specific probes for the detection of the five most 62 
clinically relevant Candida species which were capable of detecting DNA equivalent 63 
to a single genome from target fungal species in a 50µl reaction (Muir et al., 2009).   64 
 65 
The aim of this work was to develop the assay further in order to optimise conditions 66 
to allow detection of clinically relevant amounts of fungal nucleic acid in blood 67 
samples.  Fungal titres in blood can be extremely low and have been reported to be 68 
in the range of 5 – 100 colony forming units (c.f.u) ml-1 of blood (Loeffler et al., 2000).  69 
Therefore a study was performed using the C. albicans specific probe to optimise 70 
reaction conditions for detection of low amounts of C. albicans DNA and cells in 1ml 71 
spiked blood samples. 72 
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Materials and methods. 73 
Culture acquisition 74 
The type strain of C. albicans (CBS 562) species was obtained from the 75 
Centraal Bureau voor Schimmelcultures (CBS) and used for all experiments.  76 
Cultures were grown on yeast-peptone-dextrose (YPD) agar (1% yeast extract 77 
(Oxoid), 2% Mycological peptone (Oxoid), 2% glucose (Sigma), 2% Bacto agar 78 
(Difco)) at 28°C for 48 hours.  Liquid stocks of C. albicans were prepared using the 79 
following method: a growing colony was picked from YPD agar using a sterile loop, 80 
transferred to 5ml liquid YPD and incubated overnight at 28°C with shaking.  1ml 81 
samples of each culture were then aliquoted into 2ml microcentrifuge tubes.  Finally, 82 
1ml of 20% glycerol added as a cryoprotectant before transfer to -20°C storage.   83 
 84 
Steps to limit contamination 85 
 In order to prevent contamination the setup of PCR reactions was performed 86 
in a different room to where the PCR amplification was performed and in a class 2 87 
biological safety cabinet which was regularly disinfected with 70% ethanol and 88 
sterilized using ultra violet (UV) irradiation.  The air flow remained switched off while 89 
the mix was prepared to avoid contamination of samples by airborne PCR amplicon.  90 
Blood samples were aliquoted at a different site, in a laminar flow hood that was 91 
regularly sterilised as above and additionally was regularly swabbed with the DNA 92 
degrading reagent DNA-ExitusPlus (Applichem).  All stock reagents were aliquoted 93 
into working solutions to limit potential contamination and problems associated with 94 
freeze-thawing. 95 
 96 
Whole blood acquisition and treatment 97 
 Blood from a healthy donor was collected by a trained individual into 6ml 98 
K2EDTA-coated vacutainers (BD Biosciences) and inverted 8 – 10 times to ensure 99 
adequate mixing of the anti-coagulant with blood.  1ml aliquots were then pipetted 100 
into 2ml sterile cryovials and the samples stored at -80ºC until used. 101 
 102 
Extraction of DNA from liquid cultures 103 
 The QIAgen DNeasy extraction kit was used for all extractions and the 104 
manufacturer’s protocol was followed with some modifications that were appropriate 105 
for treatment of fungal material.  The yeast cell count in a stock cell suspension was 106 
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estimated by spectrometry according to the method described in Amberg et al. 107 
(2005) and a solution of approximately 5x106 yeast cells was prepared by appropriate 108 
dilution of the stock and centrifuged at 10,000 rpm for 10mins to pellet the cells.  The 109 
supernatant was removed and the cell pellet resuspended in 500ul of a lyticase lysis 110 
buffer which comprised 10U ml-1 lyticase from Arthrobacter luteus (Sigma), 50mM 111 
Tris, pH 7.5, 10mM EDTA and 28mM β-mercaptoethanol; the lyticase digestion was 112 
performed at 37°C for 30mins.  Following treatment by lyticase the sphaeroplasts 113 
were collected by centrifugation and the supernatant was removed. The disruption of 114 
the sphaeroplast cell membrane by proteinase and detergent treatments was 115 
performed according to manufacturer’s instructions and, following the addition of 116 
absolute ethanol, the samples were left on ice for 30mins to increase precipitation of 117 
DNA and enhance final yield.  The samples were then placed in silica-based spin 118 
columns and washed according to the manufacturer’s instructions.  DNA was then 119 
eluted twice from each column using 50µl of the elution buffer for each elution and a 120 
single 1.5ml tube was used to collect both eluates.  The concentration of eluted DNA 121 
was estimated by spectrometry.  All DNA was stored at -20oC. 122 
 123 
Extraction of DNA from blood samples spiked with C. albicans genomic DNA. 124 
 The required number of 1ml whole blood samples were removed from storage 125 
at -80°C and allowed to thaw.  C. albicans DNA was removed from -20°C storage 126 
and allowed to thaw.  A 5ml sterile bijou tube had the required amount of C. albicans 127 
genomic DNA added and 1ml of the blood sample was then added to the bijou.  The 128 
solution was agitated gently to allow mixing of the DNA in the blood.  Extraction of 129 
the C. albicans DNA from blood was performed using GenElute Bacterial Genomic 130 
DNA extraction kit (Sigma) with some modifications which are described below.   131 
 132 
The spiked blood samples had 2ml of a proprietary lysis buffer added and were 133 
incubated for 5mins at room temperature with occasional gentle agitation to allow 134 
mixing and complete lysis of blood cells.  Meanwhile the required number of 135 
extraction columns was prepared using Column Preparation Solution as per 136 
manufacturer’s instructions.  After the 5min incubation of blood samples 700µl of the 137 
lysate was applied to the spin column and centrifuged at 12,000g for 1min to allow 138 
DNA to bind to the column.  The flow-through was discarded.  The above step was 139 
repeated until all of the lysed blood sampled had been spun through the column.  140 
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After the final centrifugation the collection tube was discarded and replaced with a 141 
fresh one.  Wash steps were then performed as per the manufacturer’s instructions.  142 
Elution of DNA was initially performed by adding 100µl of elution buffer to the 143 
column, incubating at room temperature for 30s and centrifuging at 12,000g for 1min.  144 
30µl of this eluate was used as template in PCR reactions.  However, to improve the 145 
yield when very small amounts of C. albicans DNA were spiked into blood the elution 146 
buffer was prewarmed to 60°C and 34.25µl was applied to the spin column, 147 
incubated for 30s at room temperature and centrifuged at 12,000g for 1min.  The 148 
eluate was then reapplied to the spin column, incubated and centrifuged for a second 149 
time.  This entire eluate was then used as template in PCR amplifications. 150 
 151 
Monitoring for DNA loss and inhibition of PCR 152 
To monitor for potential loss of DNA during the extraction procedure, a 153 
comparison was made between assays performed with samples that were extracted 154 
from blood spiked with excess C. albicans DNA (37pg), and unspiked blood samples 155 
which were processed in parallel before having an excess amount (37pg) of C. 156 
albicans DNA added to the eluate.  Monitoring for potential inhibition of PCR by 157 
excess non-target DNA and/or inhibitory compounds from blood that may have co-158 
eluted with the DNA was performed by comparing the results of assays performed 159 
using DNA extracted from spiked blood samples (3.7pg C. albicans DNA) and DNA 160 
extracted from 1ml samples of sterile H2O that were spiked with an equal amount of 161 
DNA. 162 
 163 
Extraction of DNA from blood samples spiked with C. albicans cells. 164 
 To obtain cell suspensions of the appropriate number of cells to spike into 165 
blood samples, growing colonies of C. albicans were picked with a sterile loop and 166 
resuspended in 500µl sterile H2O.  This stock solution was diluted 10-fold and 50-fold 167 
and cell-density estimates of the three solutions were made using an improved 168 
Neubauer haemocytometer.  Estimates of different preparations ranged between 169 
~2x107 cells ml-1 to ~6x107 cells ml-1 and estimates were considered to be in good 170 
agreement with one another if the cell density estimates were within 0.5x107 cells ml-171 
1 of one another to allow for pipetting inaccuracies.  Provided it satisfied this criterion, 172 
the 50-fold diluted cell suspension was further diluted to yield solutions of 1 cell µl-1 173 
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and 0.1 cell µl-1.  Viable cell densities were confirmed retrospectively by performing 174 
plate counts.   175 
 176 
The extraction procedure was very similar to the method outlined above but differed 177 
in the pre-treatment step.  After thawing the blood samples, 10µl of the appropriate 178 
C. albicans cell suspension was added to a 5ml sterile bijou and then the 1ml blood 179 
sample was added and the solution gently mixed.  250µl of a lysis buffer containing 180 
200U ml-1 lyticase was added and the reaction mix incubated at room temperature for 181 
5min with gentle agitation.  After this step the extraction continued with the addition of 182 
1ml of the proprietary lysis buffer and was identical to the procedure outlined 183 
previously for genomic DNA extraction.  Note that 34.25µl of prewarmed elution 184 
buffer was always used for elution of DNA extracted from C. albicans cells. 185 
 186 
Primers and probes 187 
The previously described primers (Muir et al, 2009) ITS3.3 188 
(TGCCTGTTTGAGCGTCATTTC) and ITS4.2 (AGTCCTACCTGATTTGAGG) were 189 
used for all PCR reactions and the probe CA PR3 (ATCGCTTTGACAATGGCTTA), 190 
labelled with a proprietary ferrocene molecule linked to the 5′ terminal nucleotide by 191 
ATDBio (Southampton) was used to detect amplified target DNA. 192 
 193 
PCR conditions 194 
PCR amplification conditions used a total volume of 50µl containing the 195 
following reagents: PCR buffer (10mM Tris-HCl (pH 8.3), 50mM KCl), 100nM ITS3.3, 196 
500nM ITS4.2, 0.15mM each dNTP, 3mM MgCl2 and 2.5U Jumpstart Taq DNA 197 
polymerase (Sigma), extracted nucleic acid (30µl or 34.25µl, see above) and 198 
molecular biology grade water (Sigma) to the required volume.  The cycling 199 
conditions used were: 95°C for 1min; 94°C for 30s plus 58°C for 30s plus 72°C for 200 
1min for 40 cycles; 72°C for 3mins.  A 10μl aliquot of the PCR products was added to 201 
2µl of 6X loading dye and visualized on a 1% (w/v) agarose gel made up in Tris-202 
Borate-EDTA (TBE) buffer (0.09M Tris base, 0.09M boric acid, 2mM EDTA pH 8.0) 203 
containing 0.5µg ml-1 ethidium bromide to confirm the presence of amplified target 204 
DNA.  Samples were run at 7V cm-1.  20μl of the remaining PCR product was used 205 
for the electrochemical assay. 206 
 207 
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Electrochemistry 208 
A probe mix was prepared for each sample to be assayed containing the 209 
following reagents: 3μM of probe CA PR3 and 10U T7 exonuclease (New England 210 
Biolabs) made up to 5μl with molecular grade water (Sigma).  This probe mix was 211 
added to 20μl of PCR product and incubated for 20mins at 37°C to allow 212 
hybridization of the probe to single stranded target DNA and subsequent digestion of 213 
the duplex by T7 exonuclease.  Once incubation was complete 20μl of the probe 214 
reaction mix was pipetted onto screen printed carbon electrodes with a silver/silver-215 
chloride reference electrode.  The electrodes used for specificity testing were 216 
manufactured by Gwent Electronic Materials Ltd. and those used for sensitivity 217 
testing were manufactured by G. M. Nameplate Inc.  The observed current due to 218 
oxidation of the released ferrocene-labeled nucleotide following DPV was measured 219 
using a potentiostat (Autolab PGSTAT30, EcoChemie) and dedicated software 220 
(GPES version 4.9, EcoChemie). DPV measurements were made using the following 221 
settings: modulation time 0.04s; interval time 0.1s; initial procedure -0.1V; end 222 
potential 0.5V; step potential 0.003V; modulation amplitude 0.05V. 223 
 224 
Results 225 
Detection of excess C. albicans DNA and study of inhibitory effects 226 
Assays were carried out using excess C. albicans DNA (37pg) spiked into 227 
samples in different ways to examine the effects of the extraction procedure on the 228 
currents that were generated.  Samples that were extracted from blood spiked with 229 
excess C. albicans DNA produced a mean current of 153.4 ± 6.6nA (n=3) and this 230 
compared with a mean current of 168.9 ± 17.1nA (n=3) which was produced by 231 
samples from unspiked blood which had been processed using the extraction 232 
protocol and the eluate spiked with 37pg fungal DNA.  The PCR positive control 233 
samples - obtained by amplifying the same amount of DNA in a 50µl PCR - produced 234 
a mean current of 189.9 ± 20.7nA and an unspiked blood sample gave no current.   235 
 236 
The higher current produced by the positive control was probably as a result of the 237 
complete availability of the 37pg template in this reaction, whereas in the other 238 
reactions the 37pg template was diluted in 100µl of elution buffer.  The difference 239 
between the results obtained by spiked blood vs. spiked eluate demonstrated the 240 
effect of DNA loss due to the extraction procedure on the signals obtained in the 241 
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assay.  The difference in mean currents (15.5nA) was not significant and 242 
demonstrated that DNA retention using the procedure was good.  The zero current 243 
produced by the samples extracted from the unspiked blood confirmed that human 244 
DNA from leucocytes did not cross-react with the C. albicans-specific probe. 245 
 246 
The assays comparing currents produced by samples extracted from spiked blood or 247 
H2O demonstrated that some inhibition occurred in samples extracted from blood.  248 
The mean current produced by samples extracted from 1ml of H2O spiked with 3.7pg 249 
of C. albicans DNA was 83.1 ± 14.9nA (n=3) compared with a mean of 55.5 ± 11.5nA 250 
(n=3) produced by assays using samples extracted from 1ml blood spiked with 3.7pg 251 
DNA.  The difference in current (27.6nA) was statistically significant (P<0.05) and 252 
indicated that inhibition, either by sequestration of primers by excess human DNA or 253 
due to direct inhibition of Taq polymerase, occurred during PCR with samples 254 
extracted from whole blood. 255 
 256 
Detection of clinically relevant levels of fungal DNA from spiked blood 257 
 Assays were performed to detect DNA from clinically relevant amounts of C. 258 
albicans spiked into blood samples.  The mean currents produced by the samples 259 
spiked with 3.7pg and 370fg were 75.6 ± 8.9nA and 35.6 ± 6.4nA (≈100 and ≈10 260 
genomes respectively, n=3) and these indicated successful detection but the mean 261 
current produced with 37fg DNA was 15.0 ± 17.2nA (≈ 1 genome, n=3) which 262 
demonstrated that detection at this level was unreliable: the mean current was low 263 
and the standard deviation high due to one of the samples failing to produce a signal 264 
(i.e. 0nA current, fig 1).  With a minor adjustment to the elution stage of the extraction 265 
procedure (i.e. use of a 34.25µl eluate as template) more reliable identification of ≈1 266 
genome of C. albicans DNA in a 1ml blood sample was achieved (mean of 26.3 ± 267 
14.3nA, n=3).   268 
 269 
It was noted that there was a highly significant difference (P<0.001) between the 270 
mean current produced by the positive control which contained 3.7pg of DNA in a 271 
50µl PCR reaction compared to the mean current produced by samples which had 272 
been extracted from 1ml blood samples spiked with 3.7pg of DNA.  It was also 273 
observed that the mean current produced by the positive control was approximately 274 
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twice that of the mean current produced by the same amount of DNA spiked into 275 
blood.   276 
 277 
Detection of C. albicans cells from spiked blood samples. 278 
 Fungal cells represent the major source of fungal nucleic acid in a clinical 279 
sample so it was essential that the assay be capable of their detection.  Results of 280 
assays attempting to detect 10 c.f.u of C. albicans cells present in a 50µl reaction 281 
and spiked into a 1ml blood sample showed that detection was successful in both 282 
sample types with mean currents of 64.5 ± 45.7nA (n=3) and 16.3 ± 12.6nA (n=6) 283 
respectively.  Attempts were also made to detect suspensions containing a single 284 
c.f.u of C. albicans added to both PCR samples and 1ml blood samples but these 285 
were unsuccessful (data not shown), possibly due to the limitations inherent in the 286 
DNA extraction procedure.  This may also have accounted for the difference 287 
(P<0.0001) between the mean current of 68.5 ± 3.6nA (n=3) produced by 37fg (≈ 1 288 
genome) of C. albicans DNA in the PCR positive control and the mean current of 289 
16.3 ± 12.6nA (n=6) produced by template from the spiked blood sample which 290 
contained 10 C. albicans c.f.u’s.  291 
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 292 
Discussion 293 
 The limit of detection of C. albicans extracted DNA in blood was shown to be 294 
37fg ml-1 (≈1 genome ml-1) while the limit of detection of C. albicans cells in blood 295 
was shown to be 10 c.f.u ml-1.  The extraction method was shown to recover a good 296 
yield of the spiked C. albicans DNA from blood, and minor inhibitory effects due to 297 
co-elution of constituents from human blood were demonstrated.  There were 298 
differences observed in the mean currents obtained from samples containing 299 
equivalent amounts of nucleic acid that were prepared in different ways; the currents 300 
produced by template extracted from blood spiked with extracted C. albicans 301 
genomic DNA were higher when compared to the currents produced by assays using 302 
equivalent amounts of C. albicans c.f.u spiked into blood, while the mean currents 303 
produced by genomic DNA and whole cells added directly to PCR were higher than 304 
the currents produced by material extracted from spiked blood.  Furthermore, 305 
detection of a single C. albicans c.f.u in blood was not possible using the method. 306 
 307 
These differences could have been due in part to the effects of DNA loss occurring 308 
during the extraction procedure which would likely be more critical when lower 309 
amounts of DNA were used, or by the potential for PCR primers to be sequestered 310 
due to interactions with non-target nucleic acid which would have been provided by 311 
the large excess of human genomic DNA and RNA that would have been present in 312 
the extracted DNA sample. It was also possible that fungal 5.8S and 26S rRNA 313 
molecules that co-eluted with DNA may have inhibited PCR by competing for primers 314 
because these molecules possess the ITS3.3/4.2 primer target sites (Li et al., 1990; 315 
Metwally et al., 2008). 316 
 317 
The extraction procedure used in this initial study had not been fully optimised for 318 
detection of fungal DNA from blood samples.  In particular, due to the volume of 319 
blood and lysis buffers used, several centrifugation steps were required to process 320 
each sample which increased the risk of contamination and loss of nucleic acid and 321 
this may have been of particular importance when attempting to detect DNA from a 322 
single C. albicans cell in a 1ml blood sample.  Nonetheless, the fact that detection of 323 
fungal cells was possible using the method was a significant result and opportunities 324 
exist for optimisation of the DNA extraction procedure that may allow detection of a 325 
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single cell in blood.  Improved methodologies will probably involve immobilisation of 326 
the fungal cells on a membrane in order to remove human material and reduce the 327 
volume of sample to be processed.  Such modifications will be the subject of future 328 
research. 329 
 330 
Whole blood was used in the assay both to reduce the turnaround time and because 331 
it is a more favourable sample type for the recovery of fungal nucleic acid.  Plasma 332 
and serum samples, whilst containing fewer inhibitory substances such as human 333 
DNA and macromolecules, have the disadvantage of the removal of cell-associated 334 
fungal DNA, as well as the extra time required for preparation.  Although reports by 335 
Bougnoux et al. (1999) and Kasai et al. (2006) suggested that cell-free fungal DNA 336 
can survive in blood for relatively long periods in a rabbit model, and studies have 337 
detected cell-free fungal DNA in serum samples (Wahyuningsih et al., 2000; 338 
McMullan et al., 2008), other studies using mouse models have shown that naked 339 
DNA is rapidly cleared from the blood, mainly due to uptake by the liver but also by 340 
the action of serum-associated nucleases (Kawabata et al., 1995; Liu et al., 2007).  341 
Therefore cell-free blood fractions may be an unsuitable sample type to use.  Despite 342 
the difficulties inherent in using whole blood, our results demonstrate that detection of 343 
fungal DNA and cells is possible using the assay. 344 
 345 
While spiked blood samples from a healthy patient are useful for preliminary testing 346 
of an assay’s capability the use of clinical samples would provide much more 347 
definitive results.  Samples taken from patients with an episode of invasive candidal 348 
infection may differ from healthy blood samples, particularly in terms of the leucocyte 349 
cell population and can also provide a better measure of the sensitivity of an assay – 350 
indicating the likelihood of detection of fungal DNA from a sample taken under clinical 351 
conditions.  Further testing of the assay using clinical samples would be an essential 352 
undertaking for future work to validate this method of detection.  Additionally, the 353 
remaining probes from fungal detection suite must also be tested to demonstrate a 354 
similar range of detection of target DNA in blood samples. 355 
 356 
Nonetheless, the assay was shown to be sensitive enough to detect 37fg (≈1 357 
genome) of C. albicans genomic DNA per millilitre of blood but was less sensitive 358 
when intact cells were used, achieving a limit of detection of only 10 c.f.u per millilitre 359 
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of blood.  This detection limit is within the lower clinical range for candidaemia of 5 to 360 
100 c.f.u ml-1 (Loeffler et al., 2000) but a lower limit outside of the range would be 361 
preferable to avoid the possibility of false negative results and this may be achievable 362 
by minor adjustments to the DNA extraction procedure as suggested above. 363 
 364 
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Figure 1.  Mean currents produced in assays with DNA extracted from 1ml blood samples spiked with 456 
clinically relevant amounts of C. albicans DNA.  Error bars represent SD (n=3). 457 
